2022 : PhD in Biostatistics (Université Paris Cité)

Lingas G, Néant N, Gaymard A, Belhadi D, Peytavin G, Hites M, Staub T, Greil R, Paiva JA, Poissy J, Peiffer-Smadja N, Costagliola D, Yazdanpanah Y, Wallet F, Gagneux-Brunon A, Mentré F, Ader F, Burdet C, Guedj J, Bouscambert-Duchamp M
Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial.
The Journal of Antimicrobial Chemotherapy 2022, 77, 1404-1412.

Néant N, Lingas G, Le Hingrat Q, Ghosn J, Engelmann I, Lepiller Q, Gaymard A, Ferré V, Hartard C, Plantier JC, Thibault V, Marlet J, Montes B, Bouiller K, Lescure FX, Timsit JF, Faure E, Poissy J, Chidiac C, Raffi F, Kimmoun A, Etienne M, Richard JC, Tattevin P, Garot D, Le Moing V, Bachelet D, Tardivon C, Duval X, Yazdanpanah Y, Mentré F, Laouénan C, Visseaux B, Guedj J, FCCIaFCSg
Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort.
Proceedings of the National Academy of Sciences of the United States of America 2021, 118,

Lingas G, Rosenke K, Safronetz D, Guedj J
Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin.
PLoS computational biology 2021, 17, e1008535.

2022

Marlin R, Desjardins D, Contreras V, Lingas G, Solas C, Roques P, Naninck T, Pascal Q, Behillil S, Maisonnasse P, Lemaitre J, Kahlaoui N, Delache B, Pizzorno A, Nougairede A, Ludot C, Terrier O, Dereuddre-Bosquet N, Relouzat F, Chapon C, Ho Tsong Fang R, van der Werf S, Rosa Calatrava M, Malvy D, de Lamballerie X, Guedj J, Le Grand R
Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates.
Nature Communications 2022, 13, 5108.

Lingas G, Néant N, Gaymard A, Belhadi D, Peytavin G, Hites M, Staub T, Greil R, Paiva JA, Poissy J, Peiffer-Smadja N, Costagliola D, Yazdanpanah Y, Wallet F, Gagneux-Brunon A, Mentré F, Ader F, Burdet C, Guedj J, Bouscambert-Duchamp M
Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial.
The Journal of Antimicrobial Chemotherapy 2022, 77, 1404-1412.

2021

Driouich JS, Cochin M, Lingas G, Moureau G, Touret F, Petit PR, Piorkowski G, Barthélémy K, Laprie C, Coutard B, Guedj J, de Lamballerie X, Solas C, Nougairède A
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model.
Nature Communications 2021, 12, 1735.

Néant N, Lingas G, Le Hingrat Q, Ghosn J, Engelmann I, Lepiller Q, Gaymard A, Ferré V, Hartard C, Plantier JC, Thibault V, Marlet J, Montes B, Bouiller K, Lescure FX, Timsit JF, Faure E, Poissy J, Chidiac C, Raffi F, Kimmoun A, Etienne M, Richard JC, Tattevin P, Garot D, Le Moing V, Bachelet D, Tardivon C, Duval X, Yazdanpanah Y, Mentré F, Laouénan C, Visseaux B, Guedj J, FCCIaFCSg
Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort.
Proceedings of the National Academy of Sciences of the United States of America 2021, 118,

Lingas G, Rosenke K, Safronetz D, Guedj J
Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin.
PLoS computational biology 2021, 17, e1008535.

Bonil L, Lingas G, Coupeau D, Lucet JC, Guedj J, Visseaux B, Muylkens B
Survival of SARS-CoV-2 on Non-Porous Materials in an Experimental Setting Representative of Fomites.
Coatings 2021, 11, 371.

Driouich JS, Cochin M, Lingas G, Moureau G, Touret F, Petit PR, Piorkowski G, Barthélémy K, Laprie C, Coutard B
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model.
Nature communications 2021, 12, 1–13.